Pharmacogenetics of quetiapine
https://doi.org/10.52667/2712-9179-2021-1-1-73-83
Abstract
(1) Introduction: Quetiapine (QTP) is a dibenzothiazepine derivative, a second generation antipsychotic (AP), which is structurally similar to clozapine. The main indications for use are schizophrenia and depressive disorder. Under manic episodes in bipolar disorder can be used alone or in combination with lithium. The frequency of prescribing QTP is on average 11,987 per 100,000 population, with a positive trend in dynamics: a growth rate of more than 800% within the period 2002 to 2017.
(2) Purpose: The review of studies of pharmacogenetic pharmacokinetic and pharmacogenetic pharmacodynamic markers of QTP efficacy and safety.
(3) Materials and Methods: A search was carried out for publications of the Science Index, PubMed, Web of Science, Springer databases by keywords and their combinations over the last 10 years. In addition, the review includes earlier publications of historical interest. Despite extensive searches of these commonly used databases and search terms, it cannot be ruled out that some publications may have been missed.
(4) Results: The review considers the following pharmacokinetic markers of QTP efficacy and safety: genes are coding isoforms of cytochrome P450 (CYP2D6, CYP2C19, CYP3A4, CYP3A5), P-glycoprotein (ABCB1); pharmacogenetic pharmacodynamic markers of the efficacy and safety of QTP : genes of dopamine receptor isoform (DRD3), dopamine transporter (SCL1A1) and catecholO-methyltransferase (COMT), serotonin receptor isoforms (HTR2C), melanocortin receptor (MC4R), NOTCH protein (NOTCH4), phosphodiesterase 4D (PDE4D), SPoPL protein (SPoPL), multiple EGFlike domain (MEGF10), protocadherin-7 (PCDH7), contactin-associated protein 5 (CNTNAP5) , TRAF2 and NCK-interacting protein kinase (TNIK), spermatogenesis-associated protein 6 (SPATA6L), neurobihin (NBEA), synaptic vesicle protein-2C (SVC2) .
(5) Conclusion: Disclosure of pharmacogenetic markers of pharmacokinetics and pharmacodynamics of QTP efficacy and safety in the treatment of patients with schizophrenia and other psychiatric disorders, may provide a key to developing a strategy for its personalized prevention of adverse grug reactions (ADRs) and therapy strategy in real clinical practice.
Keywords
quetiapine,
second generation antipsychotic,
pharmacogenetics,
pharmacodynamics,
efficacy,
safety,
genes
Supporting agencies: This research received no external funding.
About the Authors
A. K. Abdyrakhmanova
V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
192019, St.-Petersburg
N. A. Shnayder
V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology;
V. F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
Russian Federation
192019, St.-Petersburg; 660022, Krasnoyarsk
N. G. Neznanov
V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
192019, St.-Petersburg
R. F. Nasyrova
V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
192019, St.-Petersburg
References
1. Pringsheim, T., Gardner, D.M. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ open 2014, 2(4), E225. doi:10.9778/cmajo.20140009.
2. Komossa, K., Depping, A., Gaudchau, A., Kissling, W., Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database of Systematic Reviews 2010. doi:10.1002/14651858. cd008121.pub2.
3. AstraZeneca Pharmaceuticals. Seroquel (quetiapine fumarate) tablets prescribing information. Wilmington, DE; 2005 Dec.
4. Suttajit, S., Srisurapanont, M., Xia, J. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database of Systematic Reviews 2013. doi:10.1002/14651858.CD007815.pub2.
5. Leucht, S., Cipriani, A., Spineli, L.,Mavridis, D., Orey, D., Richter F. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet 2013, 382(9896), 951–62. doi:10.1016/S0140-6736(13)60733-3.
6. Riedel, M., Müller, N., Strassnig, M., Spellmann, I., Severus, E., Möller, H.J. Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatric Disease and Treatment 2007, 3(2), 219–35. doi:10.2147/nedt.2007.3.2.219.
7. AstraZeneca Receives FDA Complete Response Letter on Seroquel XR for Major Depressive Disorder” (Press release). AstraZeneca 2008-12-24. https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Receives-FDA-Complete-Response-LetterOn-Seroquel-27022009.html#!.
8. Arango, C., Bobes, J. Managing acute exacerbations of schizophrenia: focus on quetiapine. Curr Med Res Opin 2004, 20(5), 619-626. doi:10.1185/030079904125003430.
9. Pringsheim, T., Gardner, D.M. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ open 2014, 2(4), E225. doi:10.9778/cmajo.20140009.
10. Heilbronn, C., Lloyd, B., McElwee, P., Eade, A., Lubman, D.I. Trends in quetiapine use and non-fatal quetiapine-related ambulance attendances. Drug and alcohol review 2013, 32(4), 405-411. doi:10.1111/dar.120287.
11. Citrome, L., Jaffe, A., Levine, J., Allingham, B., Robinson, J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004, 55, 1006–13. doi:10.1176/appi.ps.55.9.1006.
12. Rockville, M.D. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. Food and Drug Administration 2005 Apr 11. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/UCM053171.
13. Kasper, S., Müller-Spahn, F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opinion on Pharmacotherapy 2005, 1(4), 783–801. doi:10.1517/14656566.1.4.783.
14. Chew, M.L. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008, 56(7), 1333–41. doi:10.1111/j.1532-5415.2008.01737.x.
15. Guzman, F. Mechanism of action of quetiapine. Psychopharmacology Institute 2013.
16. Kapur, S., Seeman, P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?:a new hypothesis. American Journal of Psychiatry 2001, 158(3), 360–69. doi:10.1176/appi. ajp.158.3.360.
17. Quetiapine. DrugBank August 26, 2019. https://www.drugbank.ca/drugs/DB01224.
18. Gefvert, O., Lundberg, T., Wieselgren, I.M., Bergström, M., Långström, B., Wiesel F. et al. D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. European Neuropsychopharmacology 2001, 11(2), 105–110. doi:10.1016/S0924-977X(00)00133-4.
19. DeVane, C.L., Nemeroff, C.B. Clinical pharmacokinetics of quetiapine. An atypical antipsychotic. ClinPharmacokinet 2001, 40, 509-22. doi: 10.2165/00003088-200140070-00003.
20. Quetiapine (Rx) - Seroquel, Seroquel XR. WebMD. https://www.webmd.com/mental-health/news/20080506/seroquel-may-helpdepression-anxiety.
21. Quetiapine 25 mg film-coated tablets - Summary of Product Characteristics. Electronic Medicines Compendium. Sandoz January 2013. https://www.medicines.org.uk/emc/product/3079/smpc.
22. Brunton, L., Chabner, B., Knollman, B. Goodman and Gilman’s the pharmacological basis of therapeutics. New York, ed 12 2010. ISBN 978-0071624428.
23. Ascend Laboratories, LLC. Quetiapine fumarate tablet. DailyMed. Ascend Laboratories, LLC 2013. Archived from the original on 2 December 2013. Retrieved 26 November 2013.
24. Bakken, G.V., Rudberg, I., Christensen, H., Molden E., Refsum, H., Hermann, M. Metabolism of Quetiapine by CYP3A4 and CYP3A5 in Presence or Absence of Cytochrome B-5. Drug metabolism and disposition 2008, 37(2), 254-258. doi:10.1124/dmd.108.023291.
25. Van der Weide, K., van der Weide, J. The influence of the CYP3A4 *22 polymorphism on serum concentration of quetiapine in psychiatric patients . Journal of clinical psychopharmacology 2014, 34(2), 256-260. doi:10.1097/JCP.0000000000000070.
26. Shilbayeh, S., Sy, S., Melhem, M., Zmeili, R., Derendorf, H. Quantitation of the impact ofCYP3A5A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. ClinPharmacol Drug Dev 2015, 4(5), 387-394. doi:10.1002/cpdd.172.
27. Kim, K.A., Joo, H.J., Lee, H.M., Park, J.Y. Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenetics and genomics 2014, 24(1), 35-42. doi:10.1097/FPC.0000000000000020.
28. Bakken, G.V., Molden, E., Hermann, M. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients. Therapeutic drug monitoring 2015, 37(2), 256-61. doi:10.1097/FTD.0000000000000135.
29. Xu, Q., Wu, X., Li, M., Huang, H., Minica, C., Yi Z., Wang, G., Shen, L., Xing, Q., Shi, Y., He, L., Qin S. Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population. The pharmacogenomics journal 2016, 16(4), 357. doi:10.1038/tpj.2015.61.
30. Fedorenko, O.Y., Loonen, A.J., Vyalova, N.M., Boiko, А.S.,Pozhidaev, I.V., Osmanova, D.Z. Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia. Physiology and Pharmacology 2017, 21(1), 25-33. ISSN: 17350581.
31. Cabaleiro, T., López-Rodríguez, R., Román, M., Ochoa, D., Novalbos, J., Borobia, A. et al. Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. International clinical psychopharmacology 2015, 30(2), 82-88. doi:10.1097/YIC.0000000000000047.
32. González-Vacarezza, N., Dorado, P., Peñas-Lledó, E. M., Fariñas, H., Estévez-Carrizo, F. E., Lerena, A. MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers. Drug metabolism and drug interactions 2013, 28(3), 163-166. doi:10.1515/dmdi-2013-0008.
33. Saiz-Rodríguez, M., Belmonte, C., Cabaleiro, T., López-Rodríguez, R., Román, M., Ochoa, D. ABCB1 C3435T Polymorphism Affects In Different Ways The Pharmacokinetics of Antipsychotics and Antidepressants. Clinical Therapeutics 2017, 39(8), e36. doi:10.1111/bcpt.13031.
34. Zhang, Y., Ren, H., Wang, Q., Deng, W., Yue, W., Yan, H., Chen, Q., Yang G. , Lu T. , Wang L. , Zhang F., Yang, J. , Li , K., Lv, L., Tan , Q., Zhang , H., Ma, X., Yang, F., Li , L., Wang, C., Zhang, D., Zhao, L., Wang, H., Li , X., Guo, W., Hu , X., Tian , Y., Ma , X., Li , T. Testing the role of genetic variation of the MC4R gene in Chinese population in antipsychotic-induced metabolic disturbance. Science China Life Sciences 2019, 62(4), 535-543. doi:10.1007/s11427-018-9489-x.
35. Yu, H., Yan, H., Wang, L., Li, J., Tan, L., Deng, W., Chen, Q., Yang, G. , Zhang, F., Lu, T., Li Y.K., Lv, L., Tan, Q., Zhang, H., Xiao, X., Li, M., Ma, X., Yang, F., Li , L., Wang, C. , Li , T., Zhang, D., Yue, W. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. The Lancet Psychiatry 2018, 5(4), 327-38. doi:10.1016/S2215-0366(18)30049-X.
36. Allen, J.D., Bishop, J.R. A systematic review of genome-wide association studies of antipsychotic response. Pharmacogenomics 2019, 20(04), 291-306. doi:10.2217pgs-2018-0163.
37. Ramsey, T.L., Liu, Q., Massey, B.W., Brennan, M.D. Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study. Schizophr Res 2013, 149(1-3), 21-5. doi:10.1016/j.schres.2013.07.008.
Review
For citations:
Abdyrakhmanova A.K., Shnayder N.A., Neznanov N.G., Nasyrova R.F. Pharmacogenetics of quetiapine. Personalized Psychiatry and Neurology. 2021;1(1):73-83. https://doi.org/10.52667/2712-9179-2021-1-1-73-83
Views:
1921
Email this article 